ArticleExperimental neurology2026
Effect of encephalomyosynangiosis procedure on post stroke recovery in a permanent model of ischemic stroke.
Article in Experimental neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Acute ischemic stroke (AIS) remains a leading cause of disability worldwide. Limited treatments for AIS with thrombolytics are further constrained by narrow therapeutic windows and no neuroprotective effects. Damaged or underdeveloped vasculature and poor angiogenesis after AIS remains a major cause of failed neuroprotective therapy after AIS. There is a critical need for alternative approaches that enhance angiogenesis and neuroprotection to improve post-stroke recovery. Here, we use an indirect intracranial bypass technique via encephalomyosynangiosis (EMS), which involves the transposition of autologous temporalis muscle onto the ischemic cortex to stimulate angiogenesis. EMS has proven effective in moyamoya disease, and we hypothesized that it may provide sustained angiogenesis and functional recovery after AIS. We investigated the therapeutic potential of EMS in a mouse model of cortical ischemia, performed four hours after permanent distal middle cerebral artery occlusion (dMCAo). Forty-two male and female C57BL/6 mice were randomized into sham, dMCAo, and dMCAo+EMS groups. Outcomes were assessed by infarct volume quantification, cerebral perfusion imaging (laser speckle), immunohistochemical analyses of vascular density and inflammatory response, and neurobehavioral testing using open field, rotarod, and novel object recognition tasks. EMS significantly reduced infarct volume at 5 days post-stroke compared to dMCAo controls (28.5 ± 9.9 % vs. 49.3 ± 14.5 %, p < 0.05). At 30 days, EMS-treated mice demonstrated improved cerebral perfusion in perilesional regions and increased blood vessel density, accompanied by reduced IBA1+ cell accumulation. While EMS did not significantly reduce long-term cortical atrophy or affect sensorimotor function, but it improved learning and memory performance in novel object recognition tasks. In summary, EMS enhances angiogenesis, cerebral perfusion, and cognitive recovery after AIS in mice. These findings provide proof-of-concept evidence for the first time supporting EMS as a novel surgical strategy for promoting vascular repair and functional recovery following AIS, warranting further translational investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.